CD8A and neoplasm: In addition, we establish an ex vivo platform to study tumor-specific cytotoxic T lymphocyte (CTL)-mediated tumor killing and assess immunotherapeutic efficacy in co-cultured tumor organoids derived from patients with ESCC and from autologous cytotoxic CD8+ T cells (Fig. 2).